22.33 -0.59 (-2.57%)
After hours: 4:34PM EDT
|Bid||22.90 x 1400|
|Ask||22.93 x 800|
|Day's Range||22.66 - 23.69|
|52 Week Range||5.56 - 26.75|
|Beta (3Y Monthly)||-0.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.33|
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis
Veracyte, Inc. , a leading genomic diagnostics company, today announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice president, corporate and business development.
The Veracyte, Inc. (NASDAQ:VCYT) share price has had a bad week, falling 10%. But that doesn't undermine the rather lovely longer-term return, if you measure over the last three years. In fact, the share price is up a...
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
The Afirma GSC was developed using Veracyte’s novel RNA whole-transcriptome sequencing and machine learning platform. Most Hürthle cell cases yield inconclusive cytopathology results and, prior to Veracyte’s next-generation genomic test, most of these patients typically required surgery to rule out thyroid cancer.
Veracyte, Inc. today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m.
The Envisia classifier is the first commercially available test that may help distinguish IPF from other ILDs, without the need for risky surgery. The Envisia classifier recently received Medicare coverage, making it the first test of its kind for improving IPF diagnosis to be covered for the nation’s 55 million Medicare patients.
Veracyte, Inc. , a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 18th Annual Needham Healthcare Conference in New York City on Wednesday, April 10, 2019 at 8:00 a.m.
Biotech funds have stalled at key retracement levels after strong first quarter bounces and could sell off in the coming weeks, but small biotech stocks are still glued to the top of market performance lists, hitting new highs while posting outsized returns. It's wise to keep one eye on the research calendar when trading small biotech stocks with compounds in the pipeline, hitting the sidelines ahead of key dates because these issues can drop 50% or more overnight after adverse results. New York-based Axsome Therapeutics, Inc. (AXSM) researches and develops compounds and therapies for Alzheimer's disease and other central nervous system disorders.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The findings shed new light on the genomic underpinning of this rare, but aggressive, form of thyroid cancer and were presented today at ENDO 2019, the Endocrine Society's annual meeting, which is being held March 23-26 in New Orleans. “Our findings are important because they help us better understand the genomic drivers of medullary thyroid cancer,” said Steven G. Waguespack, M.D., professor of internal medicine and pediatrics at University of Texas MD Anderson Cancer Center in Houston, who presented the new data in a guided poster session.
Veracyte, Inc. (VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro expedition as part of the company’s expanded efforts to combat this disease. Through its sponsorship, the company is supporting “Team Kilimanjaro,” a group of biotechnology executives and investors that will climb Africa’s highest peak in late July 2019 to raise money for Fred Hutchinson Cancer Research Center. The Climb to Fight Cancer’s Team Kilimanjaro expedition is organized and led by Luke Timmerman, founder and editor of the Timmerman Report, a leading biotechnology newsletter.
Veracyte, Inc. announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer , will be presented at ENDO 2019, the Endocrine Society’s annual meeting.
Veracyte, Inc.'s (NASDAQ:VCYT): Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The US$851m market-cap company announced a latest loss of -US$23.0m on 31 DecemberRead More...
Veracyte (VCYT) delivered earnings and revenue surprises of 38.46% and 5.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp
Veracyte, Inc. (VCYT) announced today that it has received a final Medicare local coverage determination (LCD) for the Envisia™ Genomic Classifier. The policy was issued through the Palmetto GBA MolDx program and will become effective April 1, 2019, making the Envisia classifier covered for the nation’s 55 million Medicare patients. The Envisia classifier is the first commercially available test of its kind to improve diagnosis of idiopathic pulmonary fibrosis (IPF) and is Veracyte’s third genomic test to receive a Medicare-covered designation since the company’s founding in 2008.
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Veracyte Inc (NASDAQ: VCYT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 5:00 PM Eastern ...